 is rapidly becoming the third leading cause of cancer-related deaths, largely due to its notoriously challenging tumor microenvironment){kind=link}
Pancreatic ductal adenocarcinoma (PDAC) is rapidly becoming the third leading cause of cancer-related deaths, largely due to its notoriously challenging tumor microenvironment. This microenvironment is characterized by fibrosis, poor blood vessel formation, and immune system evasion, making conventional treatments like chemotherapy and immunotherapy often ineffective.
Researchers have developed a novel immunotherapy strategy that combines localized delivery of immune-stimulating agents, STING and TLR4 agonists, with therapies targeting the RAS gene—a common mutation in PDAC. This combination is delivered using lipid-based nanoparticles designed to penetrate the tumor’s defenses.
In preclinical models, this two-pronged approach significantly enhanced the immune response, leading to potent T cell-driven tumor regression and long-term survival. By triggering both innate and adaptive immunity, the therapy successfully overcame the tumor’s resistance mechanisms, showing potential for lasting anti-tumor effects.